Risk Factors of Daunorubicine Induced Early Cardiotoxicity in Childhood Acute Lymphoblastic Leukemia: A Retrospective Study

BACKGROUND: Daunorubicine, a type of anthracycline, is a drug commonly used in cancer chemotherapy that increases survival rate but consequently compromises with cardiovascular outcomes in some patients. Thus, preventing the early progression of cardiotoxicity is important to improve the treatment o...

Descripción completa

Detalles Bibliográficos
Autores principales: Samosir, Sunny Mariana, Utamayasa, I Ketut Alit, Andarsini, Mia Ratwita, Rahman, Mahrus A, Ontoseno, Teddy, Hidayat, Taufiq, Ugrasena, I Dewa Gede, Larasati, Maria Christina Shanty, Cahyadi, Andi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8408392/
https://www.ncbi.nlm.nih.gov/pubmed/34048168
http://dx.doi.org/10.31557/APJCP.2021.22.5.1407

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8408392/
https://www.ncbi.nlm.nih.gov/pubmed/34048168
http://dx.doi.org/10.31557/APJCP.2021.22.5.1407

Ejemplares similares